BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31440992)

  • 1. Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma.
    Huge N; Sandbothe M; Schröder AK; Stalke A; Eilers M; Schäffer V; Schlegelberger B; Illig T; Vajen B; Skawran B
    Hepatol Int; 2020 May; 14(3):373-384. PubMed ID: 31440992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
    Vafaizadeh V; Buechel D; Rubinstein N; Kalathur RKR; Bazzani L; Saxena M; Valenta T; Hausmann G; Cantù C; Basler K; Christofori G
    Oncogene; 2021 Oct; 40(43):6195-6209. PubMed ID: 34545187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma.
    Xu W; Zhou W; Cheng M; Wang J; Liu Z; He S; Luo X; Huang W; Chen T; Yan W; Xiao J
    Sci Rep; 2017 Jan; 7():40446. PubMed ID: 28074862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cytoplasmic role of Wnt/β-catenin transcriptional cofactors Bcl9, Bcl9l, and Pygopus in tooth enamel formation.
    Cantù C; Pagella P; Shajiei TD; Zimmerli D; Valenta T; Hausmann G; Basler K; Mitsiadis TA
    Sci Signal; 2017 Feb; 10(465):. PubMed ID: 28174279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling.
    Quan H; Li B; Yang J
    Biomed Pharmacother; 2018 Nov; 107():754-762. PubMed ID: 30142536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway.
    Zheng Y; Jiang L; Hu Y; Xiao C; Xu N; Zhou J; Zhou X
    BMC Cancer; 2017 Feb; 17(1):161. PubMed ID: 28241806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A positive feedback loop involving the LINC00346/β-catenin/MYC axis promotes hepatocellular carcinoma development.
    Zhang N; Chen X
    Cell Oncol (Dordr); 2020 Feb; 43(1):137-153. PubMed ID: 31691159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulated FSTL5 promotes cell proliferation and survival by affecting Wnt/β-catenin signaling in hepatocellular carcinoma.
    Zhang D; Ma X; Sun W; Cui P; Lu Z
    Int J Clin Exp Pathol; 2015; 8(3):3386-94. PubMed ID: 26045876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-26b suppresses hepatocellular carcinoma development by negatively regulating ZNRD1 and Wnt/β-catenin signaling.
    Hu X; Wang R; Ren Z; Liu X; Gu J; Cui G; Li Q
    Cancer Med; 2019 Dec; 8(17):7359-7371. PubMed ID: 31637871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-342 regulates cell proliferation and apoptosis in hepatocellular carcinoma through Wnt/β-catenin signaling pathway.
    Lu C; Jia S; Zhao S; Shao X
    Cancer Biomark; 2019; 25(1):115-126. PubMed ID: 31006667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.
    Wang X; Feng M; Xiao T; Guo B; Liu D; Liu C; Pei J; Liu Q; Xiao Y; Rosin-Arbesfeld R; Shi Y; Zhou Y; Yang M; Feng YX; Jiang Y; Shao Z; Yu K; Zhu D
    Oncogene; 2021 Apr; 40(16):2982-2997. PubMed ID: 33767438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma.
    Wei S; Dai M; Zhang C; Teng K; Wang F; Li H; Sun W; Feng Z; Kang T; Guan X; Xu R; Cai M; Xie D
    Protein Cell; 2021 Oct; 12(10):788-809. PubMed ID: 32748349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-22 and miR-214 targeting BCL9L inhibit proliferation, metastasis, and epithelial-mesenchymal transition by down-regulating Wnt signaling in colon cancer.
    Sun R; Liu Z; Han L; Yang Y; Wu F; Jiang Q; Zhang H; Ma R; Miao J; He K; Wang X; Zhou D; Huang C
    FASEB J; 2019 Apr; 33(4):5411-5424. PubMed ID: 30698996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
    Lei T; Zhu X; Zhu K; Jia F; Li S
    Cancer Biol Ther; 2019; 20(7):1007-1016. PubMed ID: 30929558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
    Cao F; Yin LX
    Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling.
    Zhao YR; Wang JL; Xu C; Li YM; Sun B; Yang LY
    Clin Sci (Lond); 2019 Jul; 133(14):1645-1662. PubMed ID: 31278131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proline-rich protein 11 silencing inhibits hepatocellular carcinoma growth and epithelial-mesenchymal transition through β-catenin signaling.
    Qiao W; Wang H; Zhang X; Luo K
    Gene; 2019 Jan; 681():7-14. PubMed ID: 30248355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/β-Catenin Signaling.
    Wang W; Li S; Liu P; Sideras K; van de Werken HJG; van der Heide M; Cao W; Lavrijsen M; Peppelenbosch MP; Bruno M; Pan Q; Smits R
    Mol Cancer Res; 2019 Feb; 17(2):521-531. PubMed ID: 30257989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.